Pharvaris N.V. (PHVS) - Stock Analysis
Last updated: Mar 29, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Large cash buffer ⢠Zero revenue ⢠Financingâdependent burn PHVS has strong cash and negligible debt supporting near-term liquidity but no revenue, large operating losses and negative FCF driven by heavy R&D, and is reliant on external financing to sustain operations.
Price Behavior
Key Price Behavior Insights: ⢠Short-term bounce ⢠Above 21-day ⢠Resistance cluster Support Level: $25.30 Resistance Level: $28.00â$28.40 The stock is staging a short-term bounceâclosing above last month's 21-day average (~$26.54) after a March low (~$25.30) but remains a recovery within a small net decline unless it sustains above the $28.00â$28.40 resistance cluster.
Sentiment & News
Key News Insights: ⢠Efficacy & safety ⢠Real-world support ⢠Growing investor interest March 2026 Lancet-published Phase 2 results, supporting real-world evidence, and increased institutional and analyst interest have strengthened deucrictibant's clinical credibility and investor momentum for Pharvaris.
AI Summary
PHVS has shifted from a speculative biotech to a binary, nearâterm eventâdriven investment where successful 1H26 onâdemand NDA filing and the 3Q26 CHAPTERâ3 prophylaxis readout are the decisive catalysts that could unlock partner deals or commercial upsideâconversely, negative or delayed outcomes would sharply increase dilution risk despite a ~USD 383M runway. Action: position only for event-driven upside, monitor NDA filing clarity, CHAPTERâ3 topline timing, and cashâraise signals; consider hedging or limiting exposure ahead of readouts.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Active | +0.0% |